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A b s t r a c t
Introduction: Percutaneous coronary intervention in high-risk patients (HRPCI) is associated with increased risk of periprocedur-
al complications such as hypotension and shock. Mechanical circulatory support devices may the bridge patient safely throughout 
the procedure and are often used in this setting.
Aim: We assessed the outcomes of patients subjected to HRPCI and supported with intra-aortic balloon pump (IABP) of larger 
volume (MEGA) compared to standard volume (STRD) or no balloon support at all (CTRL).
Material and methods: In this single-centre, open-label, randomised, controlled trial, HRPCI patients were randomly assigned to 
three groups: MEGA, STRD, and CTRL in a 1 : 1 : 1 scheme. Screening failure patients were assigned to the registry (REG). Composite 
haemodynamic endpoint (CHEP) was assessed during the procedure and major adverse cardiac even (MACE)/safety endpoints up 
to 1-year follow-up (FU).
Results: A total of 36 patients were randomised (13 MEGA, 14 STRD, and 9 CTRL). The incidence of in-hospital MACE was ob-
served in 23.1% of MEGA, 7.1% of STRD and 33.3% of CTRL (p = 0.25) patients; MACE at FU in 50.0%, 35.7%, and 55.6% (p = 0.61); 
major bleeding in 46.2%, 28.6%, and 22.2%, (p = 0.45); and CHEP in 15.4%, 50.0%, and 44.4%, respectively (p = 0.13). On per-treat-
ment (PT) analysis (16 MEGA, 10 STRD, and 21 CTRL), including 11 patients from REG, in-hospital MACE was observed in 18.8% of 
MEGA, 10.0% of STRD, and 23.8% of CTRL (p = 0.64) patients; MACE at FU in 53.3%, 20.0%, and 57.1% (p = 0.12); major bleeding in 
37.5%, 20.0%, and 33.3% (p = 0.62); and CHEP in 15.5%, 50.0%, and 52.4%, respectively (p = 0.023).
Conclusions: Larger volume intra-aortic balloon pump might be effective at reducing haemodynamic instability during HRPCI 
without a statistically significant effect on safety endpoints or MACE.
Key words: instability, hypotension, circulatory support, intra-aortic balloon pump, high-risk percutaneous coronary interven-
tion.
S u m m a r y
The inherent risk of percutanous coronary intervention performed in high-risk patients renders them vulnerable to com-
plications. Nevertheless, there is no universal consensus on whether to use mechanical circulatory support devices in that 
setting, or on which kind of device is optimum in terms of safety and efficacy. The current study supports the use of well-
known intra-aortic balloon pump technology with increased balloon volume because it probably diminishes the risk  
of significant hypotension during high-risk percutaneous coronary interventions.
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Introduction
The recent developments in percutaneous coronary 
techniques allow for treatment of very sick patients with 
complex coronary anatomy, who are not suitable candi-
dates for coronary artery bypass grafting (CABG) because 
of low ejection fraction (EF) and many comorbidities (so-
called complex high risk and indicated patients – CHIP) 
[1]. This is invariably associated with increased risk of 
acute cardiac decompensation during the procedure, it 
explains the growing interest in short-term mechani-
cal circulatory support devices (MCS). One of the best-
known examples of these is intra-aortic balloon pump 
(IABP), which was introduced to clinical practice in the 
late 1960s [2]. Its postulated mechanism of action is the 
augmentation of diastolic aortic pressure and reduction 
of left ventricular systolic and diastolic pressures, leading 
to increased coronary blood flow and decreased heart 
work, which is accompanied by a small increase in cardi-
ac output and index. Despite controversies generated by 
negative results of randomized controlled trials (RCTs), 
especially lack of mortality benefit in acute myocardial 
infarction (AMI) complicated by cardiogenic shock (CS) 
in the IABP-SHOCK-II trail [3], failure to reduce major ad-
verse cardiac even (MACE) in high-risk percutaneous cor-
onary interventions (HRPCI) patients in Balloon pump-as-
sisted Coronary Intervention Study (BCIS-1) [4], and the 
inability of myocardial preservation in anterior AMI in 
CRISP AMI studies [5], IABP is still widely used by many 
practitioners worldwide as a  valid alternative to much 
more expensive (Impella, Abiomed, Danvers, MA) or in-
vasive (ECMO) devices, which is supported by the latest 
American guidelines with a IIb/C class recommendation 
(unfortunately there are no European guidelines) [6]. The 
latest modifications of the balloon, i.e. its increased vol-
ume, direct pressure measurement by light transmission, 
and improved synchronisation with cardiac cycle, make it 
probably more effective [7].
Aim
The present study was designed to compare, in a ran-
domised fashion, outcomes of patients subjected to 
HRPCI and supported with IABP of larger volume (MEGA) 
compared to standard volume (STRD) or no balloon sup-
port at all (CTRL).
Material and methods
The study recruited patients scheduled for HRPCI 
after heart team consultation, according to clinical (not 
suitable candidates for surgery), echocardiographic (EF 
at or below 35%), and angiographic criteria (unprotected 
left main (LM), multivessel disease (MVD), or last-remain-
ing vessel or significant left main lesion with the right 
coronary artery occluded – the last two regardless of EF). 
The exclusion criteria were CS, acute coronary syndrome 
(ACS) < 48 h, aortic dissection or severe aortic regurgita-
tion, significant peripheral artery disease, acute stroke, 
or contraindications for dual antiplatelet therapy (DAPT). 
The patients were randomised in a 1 : 1 : 1 fashion 
with randomly permuted blocks using web-based rando-
misation tool [8] to support with a larger volume (MEGA: 
50 ml > 162 cm and 40 ml < 162 cm), standard volume 
(STRD: 40 ml > 162 cm and 34 ml < 162 cm), or no bal-
loon control group (CTRL). In patients allocated to balloon 
treatment the maximum balloon inflation volume and 
1 : 1 ratio of support was used throughout the procedure. 
Before PCI the right and left heart catheterisation (using 
Pulmonary Artery Catheter (PAC) via femoral or antecu-
bital fossa vein and Pigtail catheter via femoral artery, 
respectively) was done with the assessment of intra-car-
diac chamber pressures (including left ventricle systolic 
and diastolic pressures, pulmonary artery wedge pressure 
(PCWP), left ventricle pressure/time ratio (dP/dt), cardiac 
output (CO), and cardiac index (CI) by Fick principle). All 
PCIs were performed by two experienced operators in the 
Interventional Cardiology Clinic of John Paul II Hospital in 
Krakow between March 2016 and October 2017, with the 
aim of DES implantation and complete revascularisation 
according to preprocedural viability testing. The arterial 
access was either femoral or radial, preferably with 7 Fr 
sheaths. Coronary rotational atherectomy and intravascu-
lar ultrasound (IVUS) were used as needed. The invasive 
arterial pressure was constantly recorded by a separate 
line (usually radial). Procedural success was defined as re-
sidual stenosis of less than 30%, TIMI 3 flow, and no ma-
jor complications. Unfractionated heparin (70–100 U/kg) 
and DAPT were used (ticagrelor in ACS patients, clopi-
dogrel in stable coronary artery disease or when long-
term anticoagulation was indicated) as well as optimal 
medical therapy according to 2014 ESC/EACTS guidelines 
of myocardial revascularisation [9]. 
We recorded standard clinical, laboratory, angio-
graphic, and echocardiographic parameters. We assessed 
symptoms (CCS and NYHA), in hospital and one-year 
follow-up MACE (deaths, AMI or ischaemia driven re-
vascularisation, exacerbation of chronic heart failure, or 
stroke), haemorrhagic (major (≥ 3) and minor (< 3) using 
BARC scale [10]), renal, and vascular complications. To 
define MI, we used the BCIS-1 definition [11]: periproce-
dural MI (up to 72 h post intervention) was diagnosed 
when creatinine kinase MB (CK-MB) increased more than 
3× in patients with normal CK-MB at baseline or > 1.5× 
when they were already elevated. After 72 h the standard 
ESC (4th) definition of MI was used [12]. For clinical risk 
assessment we used Euroscore II [13], for angiograph-
ic complexity and risk evaluation Syntax Score [14] and 
BCIS-1 Jeopardy Score [11]. All patients were followed up 
for 12 months after PCI. 
For the purpose of this study a new haemodynamic 
composite end point was defined. First, we introduced 
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a novel hypotension index – hypotension load (HL), which 
was calculated according to the following algorithm:
1)  arterial pressure values were sampled in 10-second 
intervals,
2)  for each minute interval a  mean arterial pressure 
(MAP) value was calculated,
3)  before the PCI the patient-specific arterial hypotension 
threshold (PSAHT) was set by calculating for a mini-
mum of 5 min average MAP minus two standard de-
viations,
4)  if, during PCI, for a given minute, the MAP value was 
below PSAHT, then a hypotension episode was consid-
ered to be occurring in this minute, and the difference 
between PSAHT and MAP was calculated,
5)  HL is the sum of (PSAHT-MAP) divided by PCI duration 
time in minutes.
The arbitrary cut-off value for HL of ≥ 2 mm Hg/min 
was chosen as the first condition of a significant hypo-
tension episode. Further, we decided that a  MAP de-
crease of at least 40% of PSAHT at any time during the 
PCI (maximal hypotension episode (MHEP) = (minimum 
MAP – PSAHT/PSAHT) × 100%) also qualifies as a signif-
icant hypotension episode (second condition). Lastly, we 
took in consideration the pure clinical definition of hae-
modynamic instability (third condition), namely when hy-
potension required intervention (e.g. fluid bolus, admin-
istration of catecholamines, intubation, defibrillation, 
resuscitation, or crossover to salvage IABP therapy). All 
of above-mentioned conditions (1 to 3) together formed 
our composite haemodynamic endpoint.
The study protocol was approved by the Local Bioeth-
ics Committee.
Statistical analysis
We performed primary intension-to-treat (ITT) analy-
sis for 36 randomised patients and secondary per-treat-
ment (PT) analysis for all 47 patients (randomised and 
from the registry).
Categorical variables were presented as counts and 
percentages, and continuous variables were presented as 
mean with standard deviation or median with the first 
and the third quartile as appropriate. Normality was as-
sessed using the Shapiro-Wilk test. Equality of variances 
was tested using the Levene test. Comparisons of contin-
uous variables were preformed using analysis of variance 
or Kruskal-Wallis test as appropriate. Post hoc analysis 
was performed using Tukey’s HSD or the Steel-Dwass 
test, as appropriate. Paired analysis was performed using 
the mixed effect model. Pearson’s or Spearman’s correla-
tion coefficients were calculated, as appropriate, based 
on the normality of the data. Fisher’s exact test or the 
χ2 test were used to compare distributions of nominal 
variables. Simple logistic regression models were used to 
calculate odds ratios for the composite endpoints. A mul-
tiple logistic regression model was then constructed. All 
potential predictors were screened. All variables for which 
simple models showed a p-value less than 0.15 were can-
didates for the multiple model. A stepwise approach was 
used and minimisation of a Bayesian information crite-
rion (BIC) was used as a target. The type of balloon used 
was locked in the model. C-statistic was calculated as 
a measure of goodness of fit. Bootstrap validation was 
performed with 1000 iterations. Variance inflation fac-
tors (VIF) were calculated to measure collinearity.
All tests were two-sided, and p < 0.05 was assumed 
to indicate statistical significance. All data management 
and analysis activities were performed using JMP 14.2 
(2019, SAS Institute Inc., Cary, NC, USA) and R 3.5.3 
(R Core Team [2019]) [15]. 
Results
In the study period we were able to screen 47 pa-
tients, 36 of whom were randomised: 13 in MEGA, 14 in 
STRD, and 9 in the CTRL group. Four patients in the CTRL 
group and one patient in the MEGA group did not receive 
the allocated intervention because of severely angulat-
ed and/or calcified femoral/iliac arteries. Eleven patients 
were screening failures but finally received one of the an-
alysed treatments (MEGA, STRD, CTRL) and formed a reg-
istry (REG). Additional per treatment (PT) analysis was 
performed to control for cross-over and after adding 
REG patients, which included 47 subjects: 21 in the CTRL, 
10 in the STRD, and 16 in the MEGA group (Figure 1).
The clinical data for randomised patients is shown in 
Table I. Almost all analysed parameters were equally dis-
tributed between the study subgroups, with the excep-
tion of more frequent diagnosis of ACS and slightly great-
er EF in the MEGA group. The randomised patients were 
characterised by a very high-risk profile with a mean EF 
of 30%, median Syntax Score of 38 points, median Eu-
roscore II mortality risk of 6%, and median BCIS-1 Jeop-
ardy Score of 12.0. These baseline characteristics were 
also similar in PT analysis with no difference between 
the groups, apart from more frequent peripheral artery 
disease in the CTRL group (Table II).
There was no difference in in-hospital and follow-up 
MACE incidence on ITT analysis for randomised patients: 
MACE during hospitalisation was observed in 23.1% of 
patients in the MEGA group, 7.1% of the STRD group, and 
33.3% of the CTRL group (p = 0.25) and at FU in 50.0%, 
35.7%, and 55.6%, respectively (p = 0.61). Also, we did 
not observe any difference in safety endpoints: major or 
minor haemorrhagic complications, acute renal failure, or 
vascular complications (Table III).
The most frequent causes of major bleeds were: large 
haematoma at the vascular access site (n = 3), bleeding 
at the site of intravascular catheter without haematoma 
formation (n = 2), coronary artery perforation with car-
diac tamponade (n = 2), significant haemoglobin drop 
without obvious cause (n = 2), gastrointestinal bleeding 
Aleksander Zeliaś et al. Larger volume IABP during high-risk PCI
33Advances in Interventional Cardiology 2020; 16, 1 (59)
(n = 1), alveolar haemorrhage (n = 1), and vascular surgi-
cal intervention (n = 1).
In ITT analysis composite haemodynamic endpoint 
was achieved in 2 of 13 (15.4%) patients in MEGA, in 
7 of 14 (50.0%) patients in STRD, and in 4 of 9 (44.4%) 
patients in the CTRL group, which potentially indicates 
clinical relevance, although no statistical significance 
was achieved (p = 0.12). One patient in the CTRL group 
required urgent cross-over to IABP therapy due to shock 
(Table IV).
Due to the occurrence of crossovers a  PT set was 
formed, consisting of 16 patients in the MEGA, 10 in the 
STRD, and 21 in the CTRL group, including 11 patients 
initially assigned to REG, who finally received one of an-
alysed treatments (MEGA, STRD, CTRL). In PT analysis 
there was no difference in study endpoints: MACE during 
hospitalisation was observed in 18.8% of patients in 
the MEGA group, 10.0% of the STRD group, and 23.8% 
of the CTRL group (p = 0.64), MACE at FU occurred in 
53.3%, 20.0%, and 57.1% (p = 0.12), major bleeding in 
37.5%, 20.0%, and 33.3% (p = 0.62), and minor bleed-
ing in 12.5%, 30.0%, and 9.52%, respectively (p = 0.35) 
(Table V).
Conversely, in PT analysis, we found a  significant 
difference between the study subgroups for the occur-
rence of the composite haemodynamic endpoint (MEGA 
12.5%, STRD 50.0%, and CTRL 52.4%; p = 0.02), although 
its individual components were not different (Table VI). 
Assessed for eligibility (n = 47) 
Enrollment
Randomized (n = 36) 
Allocation
Follow-up 
Excluded – Registry (n = 11)
CTRL (n = 7), MEGA (n = 4), STRD (n = 0)
•	 Not meeting inclusion criteria (n = 6;  
1 after angio received MEGA)
•	 Declined to participate (n = 0) 
•	 Other reasons (n = 5): 1 – technical 
reasons, 4 – runthrough period before 
randomization (3 received MEGA, 1 no 
balloon)
CTRL (n = 9) 
•	 Received allocated intervention (n = 9)
•	 Did not receive allocated intervention 
(n = 0) 
Lost to follow-up (n = 0)
Discontinued intervention (n = 0) 
Lost to follow-up (n = 0)
Discontinued intervention (n = 0) 
Primary analysis ITT (36 patients) 
Secondary analysis PT (all 47 patients) 
Lost to follow-up (n = 0)
Discontinued intervention (n = 0) 
CTRL analysed (n = 9)
Excluded from analysis (n = 0) 
STRD analysed (n = 14) 
Excluded from analysis (n = 0)
STRD (n = 10)
Excluded from analysis (n = 0) 
MEGA (n = 16) (12 + 4)
Excluded from analysis (n = 0)
MEGA analysed (n = 13) 
Excluded from analysis (n = 0)
CTRL (n = 21) (9 + 7 + 5) 
Excluded from analysis (n = 0) 
STRD (n = 14) 
•	 Received a located intervention (n = 10)
•	 Did not receive allocated intervention 
(n = 4)
Reasons: too angulated and/or calcified  
iliac arteries 
MEGA (n = 13) 
•	 Received allocated intervention (n = 12)
•	 Did not receive allocated intervention 
(n = 1) 
Reasons: to angulated and/or calcified 
arteries 
Figure 1. Study flow chart
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Table I. Clinical, demographic, echocardiographic, angiographic, and procedural data (ITT)
Variable MEGA STRD CTRL Total
N (%) 13 (36) 14 (38) 9 (25) 36 (100)
Demographic data:
 Age [years], mean ± SD 71.9 ±8.3 73.3 ±11.2 67.4 ±10.5 71.3 ±10.0
 Male sex 11 (84.6) 11 (78.6) 8 (88.9) 30 (83.3)
 ACS at presentation* 10 (76.9) 5 (35.7) 3 (33.3) 18 (50.0)
Clinical symptoms:
 CCS class 3/4 9 (69.2) 11 (78.6) 3 (33.3) 23 (63.9)
 NYHA class 3/4 8 (61.5) 12 (85.7) 8 (88.7) 28 (77.8)
Past medical history:
 Hypertension 13 (100.0) 14 (100.0) 9 (100.0) 36 (100.0)
 Diabetes 4 (30.8) 9 (64.3) 4 (44.4) 17 (47.2)
 Smoking 7 (58.3) 10 (71.4) 7 (77.8) 24 (68.6)
 Previous MI 6 (46.2) 9 (64.3) 7 (77.8) 22 (61.1)
 Previous PCI 4 (30.8) 6 (42.7) 3 (33.3) 13 (36.1)
 Previous CABG 1 (7.7) 2 (14.3) 1 (11.1) 4 (11.1)
 Previous stroke 2 (15.4) 1 (7.1) 4 (44.4) 7 (19.4)
 Heart failure 7 (53.9) 10 (71.4) 8 (88.9) 25 (69.4)
 Atrial fibrillation 2 (15.4) 6 (42.9) 3 (33.3) 11 (30.6)
 Hypercholesterolaemia 11 (84.6) 10 (71.4) 6 (66.7) 27 (75.0)
 Chronic kidney disease 4 (30.8) 3 (21.4) 3 (33.3) 10 (27.8)
 Peripheral artery disease 4 (30.8) 3 (21.4) 4 (44.4) 11 (30.6)
Echo examination:
 EF (%), mean ± SD** 35 ±12 29 ±10 25 ±7 30 ±11
 Significant mitral regurg. 6 (46.2) 5 (35.7) 4 (44.4) 15 (41.7)
Risk scales:
 SYNTAx score, median (IQR) 42.0 (30.0; 52.0) 38.5 (29.6; 47.1) 36.3 (24.5; 42.8) 38.0 (29.0; 47.0)
 EUROSCORE II (%), median (IQR) 6.0 (3.0; 14.0) 7.0 (3.0; 13.0) 5.0 (3.0.0; 19.0) 6.0 (3.0; 14.0)
 BCIS-1 Jeopardy score, median (IQR) 12.0 (10.0; 12.0) 12.0 (9.5; 12.0) 10.0 (8.0; 12.0) 12.0 (8.0; 12.0)
Angiographic data:
 Left main stenosis 8 (61.5) 9 (64.3) 5 (55.6) 22 (61.1)
 CTO present 9 (69.2) 12 (85.7) 7 (77.8) 28 (77.8)
 PCI MVD (≥ 2 vessels) 10 (76.9) 10 (71.4) 7 (77.8) 27 (75.0)
 Radiation [GY], mean ± SD 2.4 ±1.6 2.3 ±1.4 2.7 ±1.7 2.4 ±1.5
 Contrast vol. [ml], mean ± SD 317 ±94 313 ±83 293 ±86 310 ±86
 No. of stents, median (IQR) 2.0 (1.15; 3.0) 2.0 (1.8; 2.3) 2.0 (1.0; 3.0) 2.0 (1.3; 3.0)
 Rotablation 3 (23.1) 4 (28.6) 1 (11.1) 8 (22.2)
 IVUS 2 (15.4) 5 (35.7) 2 (22.2) 9 (25.0)
Data are presented as number and percentage or mean value with standard deviation or median with interquartile range; *p = 0.05, **p = 0.03.
In addition, patients who had had haemodynamic in-
stability (assessed by a positive haemodynamic compos-
ite endpoint) were more likely to have periprocedural MI 
than patients who did not experience instability (33.3% 
vs. 3.4%, p = 0.01), with no difference in incidence of 
acute kidney injury (16.7% vs. 6.9%, p = 0.29).
Finally, on the PT cohort, we performed simple and 
multiple analyses for the occurrence of composite haemo-
dynamic endpoint. In a simple model we found significant 
correlations with end diastolic volume (EDV), syntax score, 
left main (LM) disease, PCI of LM, and PCI with rotablation 
and PCI complications. Then, using multiple regression 
analysis, we created a  multivariable model that showed 
that PCI with MEGA balloon in comparison to STRD or CTRL 
diminished the risk of haemodynamic composite endpoint 
and, at the same time, performing PCI of the left main 
coronary artery or rotational atherectomy increased that 
risk. The C-statistic for the final multiple model was 0.889, 
and the bootstrap C-statistic was 0.828, which indicates 
a strong model. All VIFs were smaller than 2 (the highest 
for rotablation – 1.39, and the lowest for left main – 1.22).
Cardiac index measured pre-procedurally in this mod-
el did not have any influence on haemodynamic instabil-
ity risk (Table VII).
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Table II. Clinical, demographic, echocardiographic, angiographic, and procedural data (PT)
Variable MEGA STRD CTRL Total
N (%) 16 (34) 10 (21) 21 (45) 47 (100)
Demographic data:
 Age [years], mean ± SD 71.4 ±8.4 71.3 ±11.5 71.7 ±10.1 71.5 ±9.7
 Male sex 13 (81.3) 8 (80.0) 18 (85.7) 39 (82.9)
 ACS at presentation 11 (68.8) 3 (30.0) 8 (38.1) 22 (46.8)
Clinical symptoms:
 CCS class 3/4 10 (62.5) 7 (70.0) 10 (47.6) 27 (57.5)
 NYHA class 3/4 11 (68.8) 8 (80.0) 14 (66.7) 33 (70.2)
Past medical history:
 Hypertension 16 (100.0) 10 (100.0) 20 (95.2) 46 (97.9)
 Diabetes 7 (43.8) 6 (60.0) 10 (47.6) 23 (48.9)
 Smoking 8 (53.3) 8 (80.0) 16 (76.2) 32 (69.6)
 Previous MI 8 (50.0) 6 (60.0) 13 (61.9) 27 (57.5)
 Previous PCI 5 (31.3) 4 (40.0) 7 (33.3) 16 (34.0)
 Previous CABG 2 (12.5) 1 (10.0) 2 (9.5) 5 (10.6)
 Previous stroke 2 (12.5) 0 (0.0) 6 (28.6) 8 (17.0)
 Heart failure 10 (62.5) 6 (60.0) 16 (76.2) 32 (68.1)
 Atrial fibrillation 5 (31.3) 5 (50.0) 6 (28.6) 16 (34.0)
 Hypercholesterolaemia 13 (81.3) 6 (60.0) 15 (71.4) 34 (72.3)
 Chronic kidney disease 7 (43.8) 1 (10.0) 5 (23.8) 13 (27.7)
 Peripheral artery disease* 6 (37.5) 0 (0.0) 11 (52.4) 17 (36.1)
Echo examination:
 EF (%), mean ± SD 33 ±9 29 ±11 33 ±13 32 ±11
 Significant mitral regurg. 8 (50.0) 4 (40.0) 8 (38.1) 20 (42.6)
Risk scales:
 SYNTAx score, median (IQR) 36.5 (29.1; 49.6) 38.5 (29.6; 43.0) 36.3 (27.8; 45.5) 38.0 (29.0; 44.5)
 EUROSCORE II (%), median (IQR) 8 (4; 14) 6 (2; 8) 5 (4; 15) 6 (3; 12)
 BCIS-1 Jeopardy score, median (IQR) 12.0 (9.0; 12.0) 12.0 (10.0; 12.0) 12.0 (8.0; 12.0) 12.0 (8.0; 12.0)
Angiographic data:
 Left main stenosis 11 (68.8) 6 (60.00) 15 (71.43) 32 (68.09)
 CTO present 12 (75.0) 9 (90.00) 17 (80.95) 38 (80.85)
 PCI MVD (≥ 2 vessels) 13 (81.3) 7 (70.00) 17 (80.95) 37 (78.72)
 Radiation [GY], mean ± SD 2.4 ±1.5 2.3 ±1.5 2.3 ±1.3 2.3 ±1.4
 Contrast vol. [ml], mean ± SD 317 ±89 310 ±94 295 ±71 305 ±81
 No. of stents, median (IQR) 2.0 (1.0; 3.0) 2.0 (1.0; 2.3) 2.0 (1.5; 2.5) 2.0 (1.0; 3.0)
 Rotablation 2 (12.5) 3 (30.0) 5 (23.8) 10 (21.3)
 IVUS 3 (18.8) 5 (50.0) 5 (23.8) 13 (27.7)
Data are presented as number and percentage or mean value with standard deviation or median with interquartile range; *p = 0.0036.
Discussion
The goal of circulatory support in a  high-risk PCI 
setting is to maintain a  stable haemodynamic state 
throughout the intervention by altering the myocardial 
ischaemic threshold and allowing time for complex pro-
cedure, especially when complications (embolisation, 
dissection, abrupt vessel closure, etc.) develop. Therefore, 
theoretically, the best cardiac assist device would reduce 
myocardial oxygen demand (via reductions in myocardial 
wall tension) and simultaneously increase oxygen sup-
ply by augmenting diastolic pressure and coronary blood 
flow. On the other hand, it should be easily percutane-
ously implanted and small enough to decrease the risk of 
vascular complications [16].
The present study is, to our knowledge, the only ran-
domised study comparing larger volume IABP with stan-
dard volume or no balloon support during HRPCI. Unfor-
tunately, we could not show any difference between the 
groups in ITT analysis for the occurrence of MACE during 
hospitalisation and at 1-year follow-up. This was also 
true in PT analysis replicating the results of much larger 
studies, such as BICIS-1, which recruited patients to elec-
tive standard volume IABP placement before HRPCI or to 
a  no-balloon control group. The reported 30-day MACE 
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Table III. In-hospital and follow-up MACE and safety endpoints (ITT)
Variable MEGA STRD CTRL Total P-value
N (%) 13 (36) 14 (38) 9 (25) 36 (100)
In-hospital MACE: 3 (23.08) 1 (7.14) 3 (33.33) 7 (19.44) 0.25
Cardio-vascular death 1 (7.69) 0 (0.00) 0 (0.00) 1 (2.78) 0.35
Myocardial infarction 2 (15.38) 1 (7.14) 2 (22.22) 5 (13.89) 0.57
Re-PCI 0 (0.00) 1 (7.14) 0 (0.00) 1 (2.78) 0.38
Exacerbation of heart failure 1 (7.69) 0 (0.00) 0 (0.00) 1 (2.78) 0.35
Stroke 0 (0.00) 0 (0.00) 1 (11.11) 1 (2.78) 0.24
Follow-up MACE: 6 (50.00) 5 (35.71) 5 (55.56) 16 (45.71) 0.60
Cardio-vascular deaths 2 (16.67) 2 (14.29) 4 (44.44) 8 (22.86) 0.23
Deaths (other reasons) 1 (8.33) 1 (7.14) 0 (0.00) 2 (5.71) 0.54
Myocardial infarction/RE-PCI 2 (16.67) 0 (0.00) 1 (11.11) 3 (8.57) 0.18
Exacerbation of heart failure 2 (16.67) 3 (21.43) 3 (33.33) 8 (22.86) 0.67
Stroke 1 (8.33) 0 (0.00) 0 (0.00) 1 (2.86) 0.33
In-hospital safety enpoints:
Major haemorrhages (BARC ≥ 3) 6 (46.15) 4 (28.57) 2 (22.22) 12 (33.33) 0.45
Minor haemorrhages (BARC < 3) 2 (15.38) 3 (21.43) 2 (22.22) 7 (19.44) 0.89
Vascular access complications:
Haematoma 1 (7.69) 4 (28.57) 2 (22.22) 7 (19.44) 0.34
Aneurism 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) –
A-V fistula 1 (7.69) 0 (0.00) 0 (0.00) 1 (2.78) 0.35
Acute ischaemia 2 (15.38) 0 (0.00) 0 (0.00) 2 (5.56) 0.12
Infection 1 (7.69) 0 (0.00) 0 (0.00) 1 (2.78) 0.35
Acute renal failure 2 (15.38) 1 (7.14) 0 (0.00) 3 (8.33) 0.32
Table IV. Composite haemodynamic endpoint (ITT)
Variable MEGA STRD CTRL Total P-value
N (%) 13 (36) 14 (38) 9 (25) 36 (100)
Composite haemodynamic endpoint: 2 (15.38) 7 (50.00) 4 (44.44) 13 (36.11) 0.12
HL [mm Hg/min]: 0.44
Mean ± SD 0.7 ±1.5 2.6 ±3.2 1.7 ±2.4 1.6 ±2.5
Median (IQR) 0.1 (0.00; 0.3) 1.6 (0.0; 4.4) 0.8 (0.04; 2.7) 0.14 (0.0; 2.5)
MHEP (%):   0.20
Mean ± SD –19 ±18 –34 ±26 –32 ±19 –28 ±22
Median (IQR) –17 (–25; –8) –34 (–61; –8) –24 (–48; –15) –22 (–42; –11)
Clinical instability 1 (7.69) 4 (28.57) 2 (22.22) 7 (19.44) 0.34
HL – hypotension load, MHEP – maximal hypotension episode.
rate in this trial was 15.2% in IABP and 16.0% in CTRL 
patients (p = 0.85) [4]. It needs to be stressed, however, 
that after 5 years of FU in the BICIS-1 trial the mortality 
rate in elective IABP patients was less than in the CTRL 
group (OR = 0.66, 95% CI: 0.44–0.98; p = 0.039) [17]. 
Some metanalyses also suggest that there could be mor-
tality benefit of elective IABP during HRPCI [18], but some 
others did not [19]. The debate is still ongoing whether 
more potent devices such as the Impella percutaneous 
axial heart pump (Abiomed, Danvers, MA) should substi-
tute IABP. To date, there is only one randomised trial of 
Impella 2.5 vs. IABP (standard volume) in an HRPCI set-
ting – the PROTECT II study [20], which failed to meet its 
primary 30-day composite end-point of reducing MACE 
in primary ITT analysis (30-day MACE Impella 35.1% vs. 
IABP 42.2%, p = 0.092), although secondary PT analysis 
showed superiority of the more potent device (90-day 
MACE Impella 40.0% vs. IABP 51.0%, p = 0.023). On the 
other hand, new registry studies raise further doubts on 
the percutaneous pump, showing higher rates of bleed-
ing, stroke, and even death in both HRPCI and shock in-
dication [21]. Last but not least, there is fresh evidence 
in favour of IABP – it has recently been shown that 
50 ml IABP outperformed inotropes (enoximone or dobu-
tamine) in acute heart failure patients without acute cor-
onary syndrome [22].
Our study did not show a difference in the rate of ma-
jor or minor bleedings according to BARC definitions be-
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Table V. In-hospital and follow-up MACE and safety endpoints (PT)
Variable MEGA STRD CTRL Total P-value
N (%) 16 (34) 10 (21) 21 (45) 47 (100)
In-hospital MACE: 3 (18.75) 1 (10.00) 5 (23.81) 9 (19.15) 0.63
Cardio-vascular death 1 (6.25) 0 (0.00) 0 (0.00) 1 (2.13) 0.33
Myocardial infarction 2 (12.50) 1 (10.00) 4 (19.05) 7 (14.89) 0.76
Re-PCI 0 (0.00) 1 (10.00) 0 (0.00) 1 (2.13) 0.20
Exacerbation of heart failure 1 (6.25) 0 (0.00) 0 (0.00) 1 (2.13) 0.35
Stroke 0 (0.00) 0 (0.00) 1 (4.76) 1 (2.13) 0.33
Follow-up MACE: 8 (53.33) 2 (20.00) 12 (57.14) 22 (47.83) 0.12
Cardio-vascular deaths 3 (20.00) 2 (20.00) 4 (19.05) 9 (19.57) 0.99
Deaths (other reasons) 1 (6.67) 0 (0.00) 4 (19.05) 5 (10.87) 0.14
Myocardial infarction/RE-PCI 3 (20.00) 0 (0.00) 1 (4.76) 4 (8.70) 0.13
Exacerbation of heart failure 2 (13.33) 1 (10.00) 6 (28.57) 9 (19.57) 0.36
Stroke 1 (6.67) 0 (0.00) 1 (4.76) 2 (4.35) 0.59
In-hospital safety endpoints:
Major haemorrhages (BARC ≥ 3) 6 (37.50) 2 (20.00) 7 (33.33) 15 (31.91) 0.62
Minor haemorrhages (BARC < 3) 2 (12.50) 3 (30.00) 2 (9.52) 7 (14.89) 0.35
Vascular access complications:
Haematoma 1 (6.25) 3 (30.00) 3 (14.29) 7 (14.89) 0.27
Aneurism 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) –
A-V fistula 1 (6.25) 0 (0.00) 0 (0.00) 1 (2.13) 0.33
Acute ischaemia 2 (12.50) 0 (0.00) 0 (0.00) 2 (4.26) 0.11
Infection 1 (6.25) 0 (0.00) 0 (0.00) 1 (2.13) 0.33
Acute renal failure 1 (6.25) 0 (0.00) 2 (9.52) 3 (6.38) 0.44
Table VI. Composite haemodynamic endpoint (PT)
Variable MEGA STRD CTRL Total P-value
N (%) 16 (34) 10 (21) 21 (45) 47 (100)
Composite haemodynamic endpoint: 2 (12.5) 5 (50.0) 11 (52.4) 18 (38.3) 0.02
HL [mm Hg/min]: 0.16
Mean ± SD 0.7 ±1.4 2.1 ±2.6 2.4 ±3.1 1.7 ±2.6
Median (IQR) 0.09 (0.0; 0.4) 1.2 (0.0; 4.4) 1.2 (0.1; 2.5) 0.3 (0.0; 2.5)
MHEP (%): 0.15
Mean ± SD  –19 ±18  –30 ±25 –33 ±20  –28 ±21
Median (IQR) –16 (–24; –6) –32 (–49; –6) –29 (–50; –13) –23 (–41; –11)
Clinical instability 1 (6.25) 2 (20.00) 6 (28.57) 9 (19.15) 0.19
HL – hypotension load, MHEP – maximal hypotension episode.
tween the study groups, similarly to the BICIS-1 study, as 
well as the risk of vascular and renal complications. The 
results of IABP-SHOCK II also confirm that IABP therapy is 
safe, with the same rate of major bleedings as in the con-
trol group. At the same time, as was said before, although 
more potent, the Impella pump, being larger in diameter 
than IABP, increases the incidence of vascular complica-
tions and the bleeding rate in comparison to IABP.
Because our study was not powered enough to ac-
cess hard clinical outcomes, we compared the occurrence 
of significant hypotension between the groups as a sec-
ondary outcome. Unfortunately, there is no universal 
definition of severe intraprocedural hypotension. Some 
authors defined it as a decrease of mean arterial pres-
sure below the cut-off point of 75 mmHg for at least 
10 min despite fluid resuscitation or requirement of ino-
tropic support, as was used in the BCIS-1 trial. Others 
reported severe hypotension if systolic blood pressure 
or augmented diastolic pressure (the higher of the two) 
fell below 90 mm Hg for ≥ 5 min requiring inotropic/
pressor medication or IV fluids while on device support, 
as in the PROTECT II trail. For the purpose of this study 
we introduced novel hypotension indices such as hypo-
tension load (HL), which, as we described, captures all 
hypotension episodes during the PCI in relation to the 
baseline mean arterial pressure threshold value and is 
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Table VII. Univariable and multivariable models for haemodynamic composite endpoint (PT)
Variable Odds ratio Lower 95% Upper 95% P-value
Univariable models
Parametric:
Age 1.03 0.97 1.1 0.3467
EURO score II 4.67 0 11868.53 0.7003
SYNTAx score 1.06 0.99 1.13 0.0991
Jeopardy score 1.06 0.77 1.45 0.7214
EF 1.58 0.01 279.9 0.8622
Cardiac index (echo) 0.91 0.36 2.3 0.8362
End diastolic volume 0.99 0.98 1 0.0983
E/E’ 0.97 0.89 1.05 0.4602
Hs-TnT 0.82 0.09 7.27 0.8622
CK-MB 0.96 0.87 1.05 0.3423
NT-pro-BNP 1 1 1 0.3667
Haemoglobin 1.23 0.86 1.77 0.2577
No. of stents 1.5 0.78 2.9 0.2246
Fluoro time 1.01 0.97 1.05 0.5971
Contrast volume 1 1 1.01 0.4628
Pre-PCI mean arterial pressure 0.98 0.93 1.02 0.3524
Pulmonary capillary wedge pressure 0.96 0.88 1.06 0.4157
Cardiac index (pulmonary artery cath) 0.69 0.2 2.33 0.5488
Cardiac power output 0.29 0.02 3.64 0.3342
dP/dt 1 1 1 0.9661
Non-parametric:
ACS 0.56 0.17 1.85 0.3456
Male sex 1.04 0.22 5.01 0.9594
Previous IM 2.79 0.79 9.85 0.1118
Previous PCI 1.41 0.41 4.85 0.5813
Previous CABG 1.08 0.16 7.2 0.9340
Heart failure 1.23 0.34 4.52 0.7537
Three- vs. two-vessel disease 1.28 0.21 7.82 0.7892
Left main disease 3.53 0.83 14.94 0.0868
CTO present 2.55 0.47 13.91 0.2809
PCI left main 6.5 1.26 33.58 0.0255
Rotablation 5.52 1.2 25.35 0.0282
Multivessel PCI 3.05 0.57 16.36 0.1937
PCI complications 4.33 0.92 20.32 0.0629
MEGA vs. CTRL 0.13 0.02 0.72 0.0194
VSTRD vs. CTRL 0.91 0.20 4.10 0.9013
Multivariable model:
MEGA vs. STRD 0.062 0.002 0.822 0.0342
MEGA vs. CTRL 0.032 0.001 0.343 0.0025
PCI left main 14.318 2.050 171.021 0.0057
Rotablation 15.155 1.661 234.043 0.0147
CI (echo) 0.324 0.059 1.318 0.1192
indexed for units of time and maximum hypotension 
episode (MHEP), which is the minimum pressure below 
the threshold value, which, together with pure clinical 
instability, formed our composite haemodynamic end-
point. In ITT analysis this new composite haemodynamic 
endpoint was close to reaching statistical significance, 
which potentially indicates clinical relevance. Conversely, 
in PT analysis, the observed difference was statistically 
significant, with the lowest incidence of haemodynamic 
instability in the MEGA group. Similarly, in the BICIS-1 tri-
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al there were fewer procedural complications in the IABP 
group (1.3% vs. 10.7%, p < 0.001), the majority of which 
were prolonged hypotension episodes in the no-elective 
IABP group (in 12% of cases requiring emergency IABP 
placement). On the other hand, in PROTECT II significant 
hypotension occurred in 9% of IABP patients and 4.0% of 
Impella patients, which was not statistically significant 
(p = 0.07), although cardiac power output (CPO) during 
PCI was better preserved with Impella than with IABP 
(maximal drop of CPO of –0.04 ±0.24 vs. –0.14 ±0.27, p = 
0.001, respectively). But, as was said before, a standard 
volume balloon was used. It is then probable that even 
such a small additional balloon volume could have a sub-
stantial effect on hypotension risk. The haemodynamic 
profile of larger volume balloon was studied by Kapur 
et al., who demonstrated greater augmented diastolic 
blood pressure, greater systolic unloading (which were 
both linearly correlated), and a larger reduction of PCWP 
of 50 ml balloon in respect to 40 ml in both HRPCI and 
shock patients [7]. 
To account for cross-over and after including REG pa-
tients to the PT cohort, we subsequently performed mul-
tiple regression analysis, which showed that circulatory 
support with IABP of larger volume was independently 
correlated with diminished risk of composite haemody-
namic endpoint (MEGA vs. STRD: OR = 0.062, p = 0.034 
and MEGA vs. CTRL: OR = 0.032, p = 0.002). There is ev-
idence from a recently published paper from the anaes-
thesiological field that may be clinically relevant because 
the authors, after analysing various absolute and relative 
thresholds for hypotension, showed that a  decrease of 
MAP below 65 mm Hg or below 20% from baseline were 
both related to myocardial injury after noncardiac sur-
gery (MINS) and acute kidney injury (AKI). Moreover, at 
any given threshold prolonged exposure was associated 
with increased odds of risk. At a MAP of 50 mm Hg, for 
example, just one minute was enough to significantly in-
crease the risk for both myocardial and renal injury [23]. 
In our study the composite endpoint of haemodynam-
ic instability was shown to be correlated to in-hospital 
(periprocedural) myocardial infarction, but not with AKI.
It should be stressed that all of the IABP implanta-
tions in our study were done electively before PCI had 
started, which, according to various clinical studies, es-
pecially on AMICS, would be the preferred timing for MCS 
usage, instead of inserting it only after the procedure has 
been completed [24]. On the other hand, only one of our 
patients initially randomised to the CTRL group had to be 
crossed over to IABP strategy as a consequence of severe 
haemodynamic instability.
Finally, we also demonstrated that haemodynamic 
instability was more frequent if rotational atherectomy 
was used or PCI of the left main coronary artery was 
performed, which is in line with common thoughts. But, 
rather unexpectedly, we found that cardiac index or EF 
did not have a statistically significant influence on com-
posite haemodynamic endpoint. We speculate that this 
observation could be explained by the fact that almost all 
of our patients had relatively low baseline EF (32 ±11%) 
and CI (mean: 2.6 ±0.68 l/min), and these results could 
have been different if we had recruited less sick patients 
with greater EF and CI. 
Our study has important limitations. It was designed 
as a randomised study, but due to the slow recruitment 
process (single-centre study) we were able to randomise 
only 36 patients during the study period (18 months). 
Thus, it was significantly insufficiently powered to show 
any difference in hard clinical endpoints and should be 
viewed only as a  pilot study. Moreover, we observed 
some cross-over due to inability to implant the device 
when tortuous or calcified femoral and iliac vessels were 
discovered intra-procedurally. To account for this limita-
tion, we decided to perform PT analysis and increase the 
number of patients adding subjects from the REG and 
calculate the secondary outcome of composite haemody-
namic endpoint using multiple regression models. More-
over, our composite haemodynamic endpoint is novel 
and needs further investigation to show its clinical sig-
nificance or lack thereof.
Conclusions
In this small RCT we demonstrated that elective IABP 
of larger volume type implanted electively before HRPCI 
was able to reduce composite haemodynamic endpoint 
during the procedure, but we could not show any im-
provement in hard clinical endpoints of MACE in ITT and 
PT analysis.
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